- Home
- IVVD vs TLSI Comparison
IVVD vs TLSI Comparison
Compare IVVD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- TLSI
- Stock Information
- Founded
- IVVD 2020
- TLSI 2010
- Country
- IVVD United States
- TLSI United States
- Employees
- IVVD N/A
- TLSI N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- IVVD Health Care
- TLSI Health Care
- Exchange
- IVVD Nasdaq
- TLSI Nasdaq
- Market Cap
- IVVD 116.8M
- TLSI 124.9M
- IPO Year
- IVVD 2021
- TLSI N/A
- Fundamental
- Price
- IVVD $0.44
- TLSI $4.05
- Analyst Decision
- IVVD Strong Buy
- TLSI Strong Buy
- Analyst Count
- IVVD 4
- TLSI 6
- Target Price
- IVVD $7.89
- TLSI $11.75
- AVG Volume (30 Days)
- IVVD 981.7K
- TLSI 54.4K
- Earning Date
- IVVD 11-14-2024
- TLSI 11-14-2024
- Dividend Yield
- IVVD N/A
- TLSI N/A
- EPS Growth
- IVVD N/A
- TLSI N/A
- EPS
- IVVD N/A
- TLSI N/A
- Revenue
- IVVD $11,564,000.00
- TLSI $26,891,000.00
- Revenue This Year
- IVVD N/A
- TLSI $60.97
- Revenue Next Year
- IVVD $486.65
- TLSI $53.69
- P/E Ratio
- IVVD N/A
- TLSI N/A
- Revenue Growth
- IVVD N/A
- TLSI 67.90
- 52 Week Low
- IVVD $0.40
- TLSI $3.50
- 52 Week High
- IVVD $5.20
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- IVVD 29.58
- TLSI 49.84
- Support Level
- IVVD $0.57
- TLSI $3.60
- Resistance Level
- IVVD $0.51
- TLSI $4.17
- Average True Range (ATR)
- IVVD 0.06
- TLSI 0.37
- MACD
- IVVD -0.01
- TLSI -0.03
- Stochastic Oscillator
- IVVD 13.30
- TLSI 42.31
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.